NCT06314217View on ClinicalTrials.gov

Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME

NACompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

February 18, 2024

Primary Completion Date

March 26, 2025

Study Completion Date

March 26, 2025

Conditions

Diabetic Macular Edema

Interventions

DEVICE

Everads Injector

Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector

Trial Locations (1)

Unknown

Rambam MC, Haifa

Sponsors

Lead Sponsor

Everads Therapy

All Listed Sponsors

lead

Everads Therapy

INDUSTRY